Baxter (BAX) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Baxter (BAX) over the last 10 years. The current PE ratio for Baxter as of December 08, 2017 is 26.47.
|Medical||Medical Products Manufacturing||$34.896B||$10.163B|
|Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma etc. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter products are used to provide critical, life saving and life sustaining therapies. No matter where one lives, patients with hemophilia, end stage renal disease, primary immune deficiency and a range of other diseases depend on Baxter products. This creates a common purpose among Baxter's employees worldwide: to save and sustain lives. Baxter is a leading manufacturer of intravenous (IV) solutions and administration sets premixed drugs and drug reconstitution systems, pre-filled vials and syringes for injectable drugs, electronic infusion pumps etc.|